Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Stock Information for Biomea Fusion Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biomea Fusion Inc.

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion to Participate at Jefferies London Healthcare Conference
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.